Document is current
Any future updates will be listed below
-
Authors
Parida, Pravat Kumar
Marquez-Palencia, Mauricio
Ghosh, Suvranil
Khandelwal, Nitin
Kim, Kangsan
Nair, Vidhya
Liu, Xiao-Zheng
Vu, Hieu S.
Zacharias, Lauren G.
Gonzalez-Ericsson, Paula I. https://orcid.org/0000-0002-6292-6963
Sanders, Melinda E.
Mobley, Bret C.
McDonald, Jeffrey G. https://orcid.org/0000-0003-1570-4142
Lemoff, Andrew
Peng, Yan
Lewis, Cheryl
Vale, Gonçalo https://orcid.org/0000-0003-1104-0289
Halberg, Nils https://orcid.org/0000-0002-2943-3147
Arteaga, Carlos L. https://orcid.org/0000-0003-0870-9586
Hanker, Ariella B. https://orcid.org/0000-0002-8655-8341
DeBerardinis, Ralph J. https://orcid.org/0000-0002-2705-7432
Malladi, Srinivas https://orcid.org/0000-0002-0829-2365
-
Funding
Funding for this research was provided by:
METAvivor (GAA202106-0027)
Susan G. Komen (CCR22902470))
- License Information
-
More Information
Article History
Received: 14 September 2022
Accepted: 17 April 2023
First Online: 29 May 2023
Competing interests
: A.B.H. has received research grant support from Takeda and travel support from Puma Biotechnology. C.L.A. receives or has received research grant support from Pfizer, Lilly and Takeda; holds stock options in Provista; and serves or has served in an advisory role to Novartis, Lilly, TAIHO Oncology, Daiichi Sankyo, Merck, AstraZeneca, OrigiMed, Immunomedics and Susan G. Komen Foundation. R.J.D. is a founder of Atavistik Biosciences and an advisor for Agios Pharmaceuticals, Nirogy Therapeutics and Vida Ventures. The other authors declare no competing interests.
